Checkpoint inhibitors have changed the prognosis for cancers that had few options a decade ago.
Immunotherapy represents a fundamental shift in how certain cancers are treated. Instead of attacking cancer cells directly, it removes the molecular shields that tumours use to hide from the immune system. Thailand's JCI-accredited oncology centres offer the same checkpoint inhibitors available in the US and Europe — pembrolizumab, nivolumab, atezolizumab — administered by fellowship-trained oncologists at a fraction of the cost per cycle.
Free, no-obligation — you pay the hospital directly with no markup.
Immunotherapy works by blocking the checkpoint proteins that cancer cells exploit to evade immune detection. Once these brakes are removed, T-cells can recognise and destroy tumour cells directly. The approach has produced durable responses — sometimes lasting years — in cancers that previously had poor prognoses, including advanced melanoma, non-small cell lung cancer, and renal cell carcinoma.
Not every cancer responds to immunotherapy. Biomarker testing — PD-L1 expression, microsatellite instability status, and tumour mutational burden — determines whether a patient is likely to benefit. Every case at our partner hospitals undergoes comprehensive tumour profiling and multidisciplinary review before treatment begins.
Immunotherapy drugs are expensive everywhere. Thailand provides the same agents at significantly lower cost per cycle, which compounds into major savings across a treatment course.
Same Drugs
Identical Checkpoint Inhibitors
Pembrolizumab, nivolumab, atezolizumab, and ipilimumab — the same branded drugs used in the US and Europe, sourced through regulated pharmaceutical supply chains.
50–70%
Lower Cost Per Cycle
Drug pricing, infusion charges, and oncologist fees are all substantially lower. Over a treatment course of multiple cycles, the cumulative savings are very significant.
Days
Rapid Treatment Access
Biomarker testing, tumour board review, and the first infusion can begin within days. No referral delays or funding approval wait that can extend to months at home.
Global
Coordinated International Care
English-speaking oncology teams provide detailed treatment summaries for your home doctors. Remote consultations between cycles maintain continuity of care.
We do not charge for our service — you pay the hospital directly with no markup. Immunotherapy costs depend primarily on the drug used and the number of cycles needed.
Your Quote Will Include
Prices are approximate and vary by technique, surgeon, and hospital. Your personalised quote will include a full cost breakdown.
A single cycle of checkpoint inhibitor therapy in Thailand typically costs between $3,000 and $5,400, depending on the drug, dosing protocol, and whether combination therapy is used. This compares favourably to equivalent treatment in the US, UK, and Australia.
The immunotherapy drug itself is the largest cost component. Oncologist consultation and treatment-planning fees cover clinical oversight. Infusion-suite charges cover administration and nursing supervision. Biomarker testing, blood monitoring, and coordinator support are included in the package.
The specific drug and dosing weight are the main cost drivers. Combination regimens using two checkpoint inhibitors cost more per cycle. The number of cycles varies — some patients respond after four to six cycles, while others continue for up to two years.
Typical per-cycle ranges at our partner hospitals:
Final pricing is confirmed after your oncologist reviews your pathology and recommends a protocol.
Immunotherapy in Thailand costs 50 to 70 percent less than equivalent treatment in the US ($9,000–$18,000 per cycle), Australia (A$7,500–A$15,000), and UK (£6,600–£13,500). Over a multi-cycle course, the cumulative savings make treatment accessible to patients who face cost barriers at home.
Checkpoint inhibitors are the most widely used form of cancer immunotherapy. The class of drug your oncologist recommends depends on your cancer type, biomarker profile, and whether combination treatment is appropriate.
Block the PD-1 receptor on T-cells or PD-L1 on tumour cells, restoring the immune system's ability to detect and attack the cancer. The most widely prescribed checkpoint inhibitors with established efficacy across melanoma, lung, bladder, kidney, and head and neck cancers.
Target an earlier checkpoint in T-cell activation, boosting immune response at a more upstream level. Particularly effective in advanced melanoma, both alone and in combination with PD-1 inhibitors. The immune activation is broader, which also means a higher side-effect profile that requires careful monitoring.
Two agents targeting different immune checkpoints given together to produce a more powerful anti-tumour response. Combination regimens have improved outcomes in melanoma, kidney cancer, and certain lung cancers. The trade-off is closer monitoring, as immune-related side effects are more frequent and can be more severe.
Modern immunotherapy delivery involves more than the infusion itself. Here is how our partner centres manage the treatment process from biomarker testing through to response assessment.
Comprehensive tumour profiling determines which patients are most likely to respond. PD-L1 immunohistochemistry, microsatellite instability testing, and tumour mutational burden analysis guide drug selection. This avoids exposing patients to treatment that is unlikely to work for their specific biology.
Each infusion is administered in a dedicated oncology suite with pre-medications and close nursing supervision. Post-infusion monitoring lasts at least one hour. Between cycles, blood tests screen for immune-related organ inflammation — thyroid, liver, and kidney function are checked routinely.
Checkpoint inhibitors can trigger inflammation in healthy organs — a consequence of immune activation. Your oncology team follows established grading and management algorithms. Most events respond to corticosteroids when detected early. Severe events are managed with immunosuppressive therapy under close inpatient supervision.
Each infusion takes 30 to 90 minutes, delivered in a comfortable outpatient setting. You are monitored for at least one hour afterwards for any immediate reactions. Most patients return to their accommodation the same day feeling largely normal.
Mild fatigue is the most common early symptom. Most patients carry on with light daily activities between infusions. Blood tests and a clinical review are scheduled to check organ function and screen for emerging immune-related effects.
Treatment cycles continue at intervals of two to six weeks depending on your protocol. Your oncologist tracks response through imaging and tumour markers while monitoring for immune-related inflammation. Dose adjustments are made if side effects warrant it.
After completing your treatment cycles in Thailand, your oncologist provides a comprehensive summary and monitoring plan for your home medical team. Remote consultations are available to review follow-up scans and guide any ongoing decisions.
In many cases, yes. Cycle intervals of two to six weeks allow time for travel. Your oncologist advises based on your response and side-effect profile. Carrying a treatment summary and having blood work done locally between visits is recommended.
Routine blood tests at every cycle screen for thyroid, liver, kidney, and adrenal inflammation. Skin rashes, colitis, and pneumonitis are monitored clinically. Most immune-related events are mild and respond well to corticosteroids when caught early. Severe events are managed under close medical supervision with immunosuppressive therapy.
Response is assessed through imaging scans — typically CT or PET-CT — after every two to four cycles. Some patients experience pseudoprogression where tumours appear larger initially before shrinking. Your oncologist interprets scan results in context and explains what to expect at each review.
Immunotherapy has a different side-effect profile to chemotherapy. Because it activates the immune system broadly, inflammation can occur in healthy organs. Most events are manageable when detected early.
Blood tests and clinical assessment before each cycle screen for immune-related adverse events. Your oncologist explains your individual risk profile before treatment begins and has management protocols ready for any events that arise.
Yes. Immunotherapy at JCI-accredited hospitals in Thailand follows the same international protocols and monitoring standards as leading Western cancer centres. The drugs are identical, and the oncology teams have specific experience managing immune-related adverse events.
Comprehensive biomarker testing before treatment ensures you receive the right drug. Routine blood work at every cycle catches organ inflammation early. Patients with pre-existing autoimmune conditions require careful assessment. Following your oncologist's monitoring schedule is the single most important safety measure.
Grade 3 or 4 immune-related adverse events typically require a treatment pause and corticosteroid management. Your oncologist decides whether to resume, switch agents, or discontinue based on the severity and your overall response. These decisions follow established international oncology guidelines.
Immunotherapy requires oncologists with specific experience in checkpoint inhibitor management. Here is what our partner centres provide.
Our partner hospitals run dedicated medical oncology departments with tumour profiling laboratories, infusion suites, and full emergency support. Bumrungrad International and Bangkok Hospital have extensive experience delivering immunotherapy to international patients, with pharmacies that stock the full range of approved checkpoint inhibitors.
Our partner oncologists hold board certification in medical oncology with subspecialty training in immunotherapy protocols. Many trained at international cancer centres and bring that experience to managing immune-related adverse events — the clinical skill that distinguishes good immunotherapy care from adequate care.
Confirm board certification in medical oncology and specific experience with checkpoint inhibitors for your cancer type. Ask how they monitor for immune-related adverse events and what protocols they follow if complications arise. An oncologist who provides a written treatment plan and explains biomarker results clearly is meeting the standard you should expect.
Immunotherapy response is measured objectively through imaging and biomarkers. Here is what treatment outcomes typically look like.
Response rates vary by cancer type and biomarker status. In PD-L1-high non-small cell lung cancer, response rates with pembrolizumab can exceed 40 percent. Advanced melanoma treated with combination checkpoint therapy achieves five-year survival rates above 50 percent in some trials. Not every patient responds, which is why biomarker selection matters.
Imaging assessment after every two to four cycles shows whether the tumour is responding. Durable responses — lasting months to years — are possible even after treatment stops. Pseudoprogression can occur, so early scans require careful interpretation by an experienced oncologist.
Immunotherapy involves multiple cycles over weeks to months. Some patients complete their full course in Thailand, while others split treatment between Thailand and home.
Plan for 7 to 14 days per cycle, covering biomarker testing or review, pre-infusion blood work, the infusion, post-infusion monitoring, and a follow-up assessment. If completing a full course, stays of several months may be needed. Many patients return for cycles at intervals.
Your care coordinator handles all scheduling. The quote covers oncologist consultations, the immunotherapy drug, infusion-suite use, biomarker testing, blood monitoring, supportive medications, and coordinator support. Accommodation and flights are arranged separately.
We provide detailed treatment summaries, drug protocols, biomarker results, and monitoring plans for your home medical team. If further cycles are administered locally, your home oncologist can continue without interruption using our documentation. Remote consultations with your Thai oncologist are available.
Everything you need to know before your treatment
Patient Care Director
Last reviewed: March 25, 2026
Medical disclaimer: Content on this site is provided for informational purposes and should not be treated as medical advice. Outcomes, timelines, and eligibility differ from person to person. Consult a qualified medical professional before making any decisions about surgery or treatment.
Speak with our care coordinators for a free, no-obligation consultation and personalised quote.
Speak to Our TeamTestimonials
Real experiences from patients who travelled to Thailand for treatment.
Free & No Obligation
Tell us what you're considering and we'll come back with surgeon options, pricing, and a clear plan.
Get in Touch
Tell us about the procedure you are considering and a member of our team will respond within one working day with personalised guidance.
Loading your quote form...
